Legislation in 2022 sought to expand access to the opioid use disorder treatment drug buprenorphine by eliminating previous caps on the number of patients a prescribing provider could manage and by eliminating prescriber waiver requirements. At the same time, pharmacists with prescribing authority were permitted to directly prescribe the medication without a collaborative agreement with a physician, although state-specific restrictive criteria could still apply. As a result of these changes, there was a significant increase …
Read More
